Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Medtronic's tablet-controlled pain device

The Intellis system can be programmed via a Samsung's Galaxy S2

Medtronic Samsung

Medtronic has won US approval for, and launched, a pain management implant that can be remotely controlled by a Samsung tablet.

The Intellis system treats chronic pain via neurostimulation, the level of which can be adjusted wirelessly by the Samsung Galaxy Tab S2.

Marshall Stanton, president of Medtronic's Pain Therapies division, said: "Drawing upon our 40-year legacy in SCS, the launch of the Intellis platform isn't just about a new device, but about combining cutting edge hardware with optimal therapy.”

Intellis is the world's smallest fully implantable SCS (spinal cord stimulation) neurostimulator and can also track daily activities, body positions and therapy usage to provide physicians with data on a patient’s mobility and progress.

Dr Dave Rhew, chief medical officer and head of healthcare and fitness at Samsung Electronics America, said: "We are excited to partner with Medtronic in their aim to simplify programming, and streamline therapy management with the Intellis platform.

"Samsung's Galaxy tablets-secured by the HIPAA-ready Samsung Knox mobile security platform-will support future Medtronic therapies and over the air (OTA) software upgrades to ensure clinicians using Intellis have access to the most up-to-date solutions."

The two firms have previously worked together in diabetes, to develop a range of solutions to enhance management of the condition.

Article by
Dominic Tyer

21st September 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics